Effects of short-term reserpine treatment on generalized and focal dystonic-dyskinetic syndromes.
We report that low dose reserpine treatment (0.25 mg/day for 7 days) improves the dystonic-dyskinetic disability score in patients affected by idiopathic dystonias, iatrogenic dystonic-dyskinetic syndromes and Sydenham's chorea. The results support the idea that the particular antidopaminergic activity exerted by reserpine or other dopamine-depleting agents may produce good therapeutical efficacy, although reserpine can precipitate Parkinsonism and induce dopamine-receptor supersensitivity.
Raffaele
R
R
Institute of Neurology, University of Catania, Italy.
Patti
F
F
Sciacca
A
A
Palmeri
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000627:therapeutic use; D002819:Chorea / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008090:Lisuride / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy*; D012110:Reserpine / Q000008:administration & dosage / Q000627:therapeutic use*; D013577:Syndrome; D013997:Time Factors
D001971:Bromocriptine; D007980:Levodopa; D012110:Reserpine; D008090:Lisuride